Additional file 1 of Dimeric Her2-specific affibody mediated cisplatin-loaded nanoparticles for tumor enhanced chemo-radiotherapy
Creators: name: Wang, Haijun
name: Jia, Dianlong
name: Yuan, Dandan
name: Yin, Xiaolei
name: Yuan, Fengjiao
name: Wang, Feifei
name: Shi, Wenna
name: Li, Hui
name: Zhu, Li-Min
name: Fan, Qing
Publisher: name: figshare
Year: 2021
Subjects: subject: Biophysics
subject: Space Science
subject: Medicine
subject: Cell Biology
subject: Molecular Biology
subject: Pharmacology
subject: Chemical Sciences not elsewhere classified
subject: Immunology
subject: FOS: Clinical medicine
subject: Cancer

description: Additional file 1: Fig. S1. (a) N2 adsorption/desorption isotherms of mPDA NPs and (b) the corresponding pore-size distribution curves. (c) Zeta potential values of cisplatin, mPDA, Pt@mPDA, Pt@mPDA/MnO2 and Pt@mPDA/MnO2/PDA NPs dispersed in water (pH 7.4). Fig. S2. (a) XPS full survey spectra and (b) Mn 2p XPS spectra of mPDA/MnO2/PDA NPs. Fig. S3. UV–Vis absorption spectra of Pt@mPDA/MnO2/PDA NPs in (a) blank PBS (pH 7.4) and PBS (pH 7.4) containing (b) 1 mM H2O2, (c) 2 mM GSH, (d) 1 mM H2O2 + 2 mM GSH, and (e) 1 mM H2O2 + 5 mM GSH at different time points; (f) the absorption spectra comparison of aqueous dispersions of NPs after 14 d under different conditions. Fig. S4. UV–Vis absorption spectra of MB solution after treating with X-ray (6 Gy), Pt@mPDA/PDA NPs + X-ray (6 Gy), Pt@mPDA/MnO2/PDA NPs, and Pt@mPDA/MnO2/PDA NPs + X-ray (6 Gy) for 30 min. Blank MB solution was used as control. Fig. S5. (a) DLS sizes of Pt@mPDA/MnO2/PDA and Pt@mPDA/MnO2/PDA-ZHer2 NPs in water. (b) DLS sizes of Pt@mPDA/MnO2/PDA and Pt@mPDA/MnO2/PDA-ZHer2 NPs in PBS over 24 h; Fig. S6. FCM data for (a) MCF-7 or (b) SKOV-3 cells after treatment with PBS, 2 or 4 μg/mL of FITC-labelled anti-Her2 antibody for 2 h and showing the corresponding quantified fluorescence intensity. (c) Fluorescence images for MCF-7 or SKOV-3 cells after treatment with PBS and 2 or 4 μg/mL of FITC-labelled anti-Her2 antibody for 2 h. Fig. S7. (a) CLSM images of MCF-7 and SKOV-3 cells after 2 h incubation with FAM-ZHer2. (b) Flow cytometry data for: untreated SKOV-3 cells; SKOV-3 cells incubated for 2 h with FAM-ZHer2 and cells pre-incubated with ZHer2 for 1 h before being exposed to FAM-ZHer2 for 2 h, and corresponding quantified fluorescence intensity. Fig. S8. (a) Flow cytometry data for: untreated SKOV-3 cells; SKOV-3 cells incubated for monomeric (in the presence of 2-ME) or dimeric (in the absence of 2-ME) FAM-Her2 affibody at 37 °C for 2 h. (b) MTT viability results for HUVECs treated with different concentration of mPDA/MnO2/PDA-ZHer2 NPs. Fig. S9. (a) Microscope images of RBCs incubated with (II) PBS, (II) Triton-100, (III) Pt@mPDA/MnO2/PDA NPs, (IV) Pt@mPDA/MnO2/PDA-ZHer2 NPs and (b) corresponding pictures after centrifugation (5000 rpm, 10 min). (c) Hemocompatibility data. Fig. S10. Biodistribution of free cisplatin (Pt), Pt@mPDA/MnO2/PDA and Pt@mPDA/MnO2/PDA-ZHer2 NPs in mice bearing SKOV-3 tumor grafts. Fig. S11. Representative H&amp;E-stained images of the major organs collected after in vivo chemotherapy experiment. Fig. S12. Blood biochemical analyses of the mice from chemotherapy experiment.